Catalyst Pharmaceuticals Announces Proposed Settlement of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Catalyst Pharmaceuticals Announces Proposed Settlement of Pending Securities Class Action Lawsuit

CORAL GABLES, Fla., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) (Catalyst Pharmaceuticals or the Company), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it has entered into a memorandum of understanding ("MOU") to settle its pending class action securities lawsuit.

As previously disclosed, the Company and one of its executive officers are defendants in a class action lawsuit filed in the U.S. District Court for the Southern District of Florida. The amended complaint purports to state a claim for alleged misrepresentations regarding the development of Firdapse™ on behalf of a class of those who purchased shares of the Company's common stock between August 27, 2013 and October 18, 2013.

Catalyst Pharmaceuticals has entered into a MOU with the lead plaintiffs in the class action lawsuit under which the parties have agreed, subject to execution of a formal stipulation of settlement and approval of the Court, to settle the lawsuit. Under the MOU, Catalyst Pharmaceuticals has agreed, subject to court approval, to pay $3.5 million in return for a dismissal and release of all claims against the defendants. Because the settlement payment is expected to be paid in full by Catalyst Pharmaceuticals' insurance carrier, it is not expected that the settlement will have any material impact on Catalyst Pharmaceutical's financial position or results of operations. The stipulation of settlement to be filed with the Court will include an acknowledgement that the defendants do not admit any liability by entering into such stipulation of settlement, and the defendants continue to deny all of the allegations against them and to maintain that the suit has no merit.

Patrick J. McEnany, Catalyst Pharmaceuticals' Chairman and CEO, stated: "We believe that we would have prevailed if the litigation had proceeded. However, in light of the potential costs of continued litigation, as well as the potential burden and disruption to the Company and its management, Catalyst, together with its insurance carrier, believed that it made sense to settle the case for the amount set forth in the settlement agreement."

If the proposed settlement is approved by the Court, a notice to class members will be sent with information regarding the allocation and distribution of the settlement funds and with instructions on procedures to follow to make a claim on the settlement fund.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, recently completed testing in a global, multi-center, pivotal Phase 3 trial and announced positive top-line data. Firdapse™ for the treatment of LEMS, has received Breakthrough Therapy and Orphan Drug Designations from the U.S. Food and Drug Administration (FDA). Firdapse™ is the first and only European approved drug for symptomatic treatment in adults with LEMS.

Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including the ability to document the settlement and obtain Court approval of the settlement, the extent to which individual claimants will opt out of the class and pursue individual claims, the ability to overcome objections or appeals regarding the settlement, whether the receipt of breakthrough therapy designation for Firdapse ™ will expedite the development and review of Firdapse ™ by the FDA or the likelihood that the product will be found to be safe and effective, whether an NDA for Firdapse ™ will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether Catalyst will be the first company to receive an approval for amifampridine 3,4-DAP, giving it 7-year marketing exclusivity for its product, whether any of Catalyst's product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2013 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Investor Contacts Brian Korb The Trout Group LLC (646) 378-2923 Media Contacts David Schull Matt Middleman, M.D. Russo Partners (212) 845-4271 (212) 845-4272 Company Contact Patrick J. McEnany Catalyst Pharmaceutical Partners, Inc. Chief Executive Officer (305) 529-2522

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 257

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 15

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 138

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 46

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 297

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 0

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 25

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 26

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading

Top 5 Most Recently Viewed Articles

HydrogenPro ASA Reports Strong Q4 2024 Financial Insights

Updated Category News Views 205

HydrogenPro ASA's Financial Results Overview HydrogenPro ASA (OSE: HYPRO) recently revealed its remarkable financial outcomes for the fourth quarter of 2024, showcasing a solid performance despite the challenges faced in the industry. This quarter highlights the company’s resilience and strengthens its position in the global hydrogen market. Key Achievements in Q4 2024...

Continue Reading
Angioplasty Balloons Market: $3.6B by 2033? Unpack the Growth!

Updated Category News Views 174

February 18, 2026—mark it down: the angioplasty balloons market is gearing up to swell from a cool $2.6 billion in 2023 to a whopping $3.6 billion by 2033 at a steady CAGR of 3.4%. Why? Well, take your pick: rising cardiovascular disease prevalence, a geriatric boom, and increasingly tech-savvy procedures are all fueling this surge. What’s Pumping Up Growth?...

Continue Reading
Norges Bank Transitions to Major Shareholder in NKT A/S

Updated Category News Views 175

Significant Shareholding Changes in NKT A/S In a recent announcement that has stirred interest in the investment community, it has come to light that Norges Bank has increased its holdings in NKT A/S. This announcement is significant as it illustrates the dynamic changes within major shareholding structures in public companies. Understanding the Acquisition NKT A/S has...

Continue Reading
Novo Nordisk Strengthens Shareholder Value with Buyback Plan

Updated Category News Views 103

Introduction to Novo Nordisk's Share Repurchase Program Leading healthcare company Novo Nordisk has embarked on an ambitious share repurchase program to strengthen its shareholder value. This initiative, aligning with European financial regulations, showcases the company's commitment to enhancing shareholder returns. The overall plan involves a substantial repurchase...

Continue Reading
Unlocking Potential: Monthly Dividend Strategies for Retirement

Updated Category News Views 189

Maximizing Monthly Income for Retirement Imagine enjoying monthly dividends that accumulate annual yields ranging from 7.2% to 15.4%. It’s enticing, especially for those looking for a steady stream of income during retirement. With the current market filled with uncertainty, many investors are skittish and hesitant to put their money into traditional investments. This...

Continue Reading